Navigation Links
NIH expands nationwide network of Vaccine and Treatment Evaluation Units
Date:9/26/2013

A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. With these new awards, NIAID will increase the number of funded institutions from eight to nine and expand the ability of the VTEUs to conduct research in domestic and international research locations, including resource-poor settings.

Each institution has the potential to receive funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, estimated to be up to $135 million annually over a seven-year period.

"The VTEUs have been an invaluable resource for testing important vaccines and treatments against deadly emerging infectious disease threats," said NIAID Director Anthony S. Fauci, M.D. "Through these new awards, we are increasing the network's capacity to study infectious diseases where they are endemic. This will allow us to learn more about the origin and evolution of emerging diseases and also improve the evaluation of diagnostics along with potential vaccines and treatments."

Established in 1962, the VTEUs have conducted hundreds of clinical trials, many of which have contributed to vaccine licensure. VTEU investigators have tested vaccines and therapeutics for diseases such as influenza, pneumonia, pertussis, Haemophilus influenzae Type B infection, cholera, anthrax, malaria and tuberculosis. Childhood vaccines and combination vaccinesthe delivery of several vaccines through one inoculationhave been and remain an important part of the VTEUs' research goals.

For example, the network is evaluating the safety of and immune response generated by the pertussis vaccine Tdap in pregnant women and the effect of immunizing expectant mothers on their infants' immune responses to DTaP, the pertussis vaccine that is routinely administered to children.

In 2001, responding to biodefense concerns, the VTEUs conducted a trial that showed that stockpiled smallpox vaccine could be diluted up to five times and retain its potency, which meant that the original 15.4 million doses were actually enough to protect 77 million people from smallpox infection. More recently, when a new strain of H1N1 influenza emerged in 2009, the VTEUs initiated a series of clinical trials to assess the safety of and immune system response to various dosing regimens of candidate vaccines in healthy adults, elderly people and healthy children. The results of these trials were made available within a few months and helped public health officials and policy makers determine the most appropriate dose of vaccine. Earlier this month, the VTEUs launched two clinical trials to evaluate an investigational vaccine against the H7N9 avian influenza virus that emerged in humans in China earlier this year.

"Launching and obtaining results from such studies quickly is possible because the VTEUs have proved that they can rapidly enroll large numbers of participants. This agility is especially important for testing vaccines designed to counteract emerging infectious diseases of public health concern," said Dr. Fauci.

The newly awarded VTEU sites and principal investigators (PIs) are as follows:

  • Baylor College of Medicine, Houston
    PI: Wendy A. Keitel, M.D.

  • Cincinnati Children's Hospital Medical Center
    PI: David I. Bernstein, M.D., M.A.

  • Duke Medicine [new to VTEU program], Durham, N.C.
    PI: Emmanuel B. Walter, M.D., M.P.H.

  • Emory University, Atlanta
    PI: Mark J. Mulligan, M.D.

  • Group Health Research Institute, Seattle
    PI: Lisa A. Jackson, M.D., M.P.H.

  • Saint Louis University
    PI: Robert B. Belshe, M.D.

  • University of Iowa, Iowa City
    PI: Patricia L. Winokur, M.D.

  • University of Maryland, Baltimore
    PI: Karen L. Kotloff, M.D.

  • Vanderbilt University, Nashville
    PI: Kathryn M. Edwards, M.D.


'/>"/>

Contact: Nalini Padmanabhan
padmanabhannm@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Data release from the Allen Institute for Brain Science expands online atlas offerings
2. Financial Press: Bralorne Gold Mines Strikes Expands on its Ultra-High Grade Gold System in Canada
3. Mahvrick Expands to Brazil, Russia, India, China to Support Existing Client Customer Growth
4. U.S. Expands SIDS Prevention Effort
5. Center For Sight Expands Services in University Park; David Hunt, O.D., Becomes Part of Center For Sight’s Comprehensive Eye Care Team
6. US Drug Watchdog Expands Their Transvaginal Mesh Initiative Because Of The Potential Number Of Victims & They are Offering the Names of the Best Women Attorneys To Help
7. Southport Family Dental Expands Team with New Dentist
8. Norah Guide Expands Transit Guide Reports for Extended Readings to Customers
9. Nursing Home Complaint Center Now Expands Their Initiative Focused On Sepsis Victims In Nursing Homes And Urges Families To Be On The Lookout For Bed Sores
10. KORT Physical Therapy Expands Services to Include In-Home Physical Therapy
11. Everyday Vitamin Nutrition LLC Expands Offerings to Bring 100% Natural Cosmeceutical and Beauty Products to Customers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: